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Abstract B cell-activating factor (BAFF), a proliferation-
inducing ligand (APRIL) and apoptosis-inducing ligand
(TRAIL) were demonstrated in several haematological dis-
eases including acute myeloid leukemia (AML). Those cyto-
kines are capable of activating a broad spectrum of intracel-
lular signalling cascades that can either induce apoptosis or
protect from programmed cell death. We have analysed
BAFF, APRIL and TRAIL serum concentrations in 76 pa-
tients with newly diagnosed AML and 40 healthy volunteers.
The values were significantly higher for APRIL and BAFF
but lower for TRAIL compared to healthy volunteers.
Induction therapy significantly reduced the values for BAFF
and increased them for TRAIL. Moreover, the concentration
of BAFF and APRIL was significantly lower and the concen-
tration of TRAIL higher in a group of patients with complete
remission compared to non-respondent AML patients. In ad-
dition, higher concentrations of BAFF and lower of TRAIL
predicted a shorter overall survival, suggesting thereby an
important prognostic marker and possible therapeutic target
in AML.
Keywords Acute myeloid leukaemia . APRIL . BAFF .
TRAIL
Introduction
Acute myeloid leukaemia (AML) represents a group of clonal
haematopoietic stem cell disorders in which both failure to
differentiate and overproliferation in the stem cell compart-
ment result in the accumulation of non-functional myeloid
cells termed myeloblasts and loss of normal haematopoietic
function. Considerable effort has been invested in identifying
prognostic markers that might predict clinical outcomes in
AML patients. There are currently several characteristics, such
as advanced age, cytogenetic and performance status, that are
commonly used as predictors of survival [1, 2].
Two decades ago, the existence of receptors activated by the
tumour necrosis factor alpha (TNF-α) was demonstrated for
several haematological diseases, including AML cells [3, 4].
Importantly, there are different effects of the TNF-α which can
be observed in AML blasts. The cytokine TNF-α is capable of
activating a broad spectrum of intracellular signalling cascades
that can either induce apoptosis (e.g. activation of caspase-8) or
protect various cell types from programmed cell death (e.g.
nuclear factor-kappa B (NF-κB) pathway activation) [5].
NF-κB activation is predominantly responsible for the expres-
sion of anti-apoptotic genes. Nevertheless, some proapoptotic
genes, including Fas ligand or TRAIL, TNF-κ and p53, are
targeted by NF-κB too [6].
TNF-related apoptosis-inducing ligand (TRAIL) molecule,
which belongs to the TNF family of proteins, participates in the
elimination of neoplastic cells, including leukaemic cells, in 60%
of cases [7, 8]. TRAIL, also known as Apo-2L, can be biolog-
ically effective as an integral membrane protein (mTRAIL,
32 kDa), as well as a soluble cytokine (sTRAIL, 24 kDa) [8].
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Several important functions of TRAIL-induced apoptosis have
been reported. First, TRAIL-mediated cytotoxicity plays an im-
portant role in innate and adaptive immune responses [9].
Second, TRAIL exerts a regulatory function on erythroid and
myeloid maturation in normal haematopoiesis [10–13].
Moreover, senescent neutrophils are eliminated by TRAIL-
induced apoptosis upon their return to the bone marrow [14].
The anti-tumour activity of TRAIL has been investigated in
haematological malignancies, including multiple myeloma
cells and Philadelphia chromosome-positive leukaemia, in
which TRAIL was shown to be able to induce apoptosis [15,
16]. A few studies, carried out on a limited number of cases,
exhibited a very low sensitivity of AML blasts to the apoptotic
effects of TRAIL [17]. By contrast, some continuous cell lines
derived from AML were observed to have a pronounced
sensitivity to the TRAIL-mediated apoptotic effects [18].
B cell-activating factor (BAFF) and a proliferation-
inducing ligand (APRIL), both members of the TNF family,
produce an effect opposite to that of TRAIL. They represent
two of the main survival factors for immature, naive and
activated B cells [19]. BAFF, APRIL and TRAIL molecules
were also detected in monocytes/macrophages, dendrite cells
and activated T lymphocytes [7, 20]. Another significant
source of these molecules is neutrophils, which participate in
the early stage of anti-cancer response [21]. BAFF and APRIL
are also known to directly activate the NF-κB pathway [22,
23]. There is some evidence that this pathway activity is also
observable in the CD34+ AML cells [22]. Consequently, the
inhibitors of NF-κB have emerged as potential therapies
against AML. Depending on the B cell maturation stage,
BAFF was reported to induce the anti-apoptotic proteins
Bcl-2, A1 and Bcl-xL and to reduce the proapoptotic protein
Bak [24, 25]. The not yet fully understood role of BAFF,
APRIL and their receptors in normal B cell homeostasis and
in several tumour models raises the possibility of their in-
volvement in the pathogenesis of haematological malignan-
cies and solid tumours.
Indeed, it has been demonstrated that APRIL mRNA and
its protein, including its secreted form, are expressed in the
leukaemic cells of patients with AML subtypes but not in
normal haematopoietic progenitors. Retrovirus-mediated
APRIL expression in normal haematopoietic progenitors con-
fers resistance to the chemotherapeutic drug-induced apopto-
sis. Conversely, blocking APRIL function by recombinant
soluble APRIL receptors increased the chemotherapeutic
drug-induced cell death in AML cells [26].
The purposes of the present study were to evaluate serum
levels of BAFF, APRIL and TRAIL in healthy volunteers and
in AML patients with varying severity of the disease in order
to determine whether there was any correlation between
BAFF, APRIL and TRAIL at diagnosis and some prognostic
biological parameters of AML patients and to explore their
clinical significance in predicting the disease activity of AML.
Patients
Seventy-six patients with newly diagnosed acute non-
promyelocytic leukaemia were included in the study. Their
median age at the time of sample collection was 45.5, and the
range was 18–62. Thirty-nine subjects were female and 37
male. Both patients with acute promyelocytic leukaemia, due
to the specific biology and a different outcome, as well as
AML patients who received corticosteroids at the beginning
of the treatment course had been excluded from the study.
Diagnoses were established following theWHO classification
system [27]. Blood counts and flow cytometry were per-
formed in order to confirm the presence of blastic cells,
whereas cytogenetic and molecular studies, including the
FISH study (AML1/ETO, CBFß/ MYH11, MLLT3-MLL
and frequently mutated genes FLT3-ITD, NPM1, CEBPA),
determine the risk group, according to WHO recommenda-
tion. On the basis of the above, patients were classified as
follows: 13 (17 %) patients had good risk (10 patients with
t(8;21), 2 with inv(16) and one with mutated core-binding
factor leukaemia (CEBPAmut), 17 (22.5 %) subjects had first
intermediate risk (diploid karyotype features with 4 both
mutated nucleophosmin (NPM1mut) and internal tandem du-
plication of Fms-like tyrosine kinase 3 (FLT3-ITD) and 9 with
FLT3-ITD without NMP1mut), 13 (17 %) patients had second
intermediate risk (3 patients with t(9;11) and 10 with different
abnormalities not assigned to either good or bad risk group)
and 33 subjects (43.5 %) were classified as unfavourable risk
group with del(5q), del(7q) or complex (≥3) abnormalities.
AML patients were treated in the Haematology Department of
the Medical University of Bialystok from 2007 to 2012 with
7-day induction chemotherapy regimens corresponding to the
standard therapy based on the Polish Adult Leukaemia Group:
Cytarabine was delivered as a continuous IV infusion for
seven consecutive days at a dose of 200 mg/m2, while
anthracycline for three consecutive days as an IV push at a
dose of 50 mg/m2, cladribine was administered for 5 days as
an IV push at a dose of 5 mg/m2 (DAC schedule) [28]. After
induction, the morphology response was evaluated following
the recommendation by Chason et al. [29]; 44 patients
achieved complete remission (CR) after first induction and
27 were non-responders (NR). Among all patients included in
the study, there were no patients with partial remission.
Patients who did not achieve CR were given re-induction
(CLAG-M or/and ICE). All patients who achieved CR after
first/second/third induction received two consolidation thera-
pies: first HAM (cytarabine and mitoxantrone) and second
HDAraC (high dose of cytarabine), prior to allogeneic stem
cell transplantation (50 patients) or maintenance therapy in the
case of patients with favourable cytogenetic risk (9 patients).
The mortality during first/second/third inductions and consol-
idations stood at 5/5/3/0 patients. The characteristic of the
patients is listed in Table 1.
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The control group was population-based and comprised
forty age-matched healthy volunteers (20 males, 20 females).
Samples were collected from the subjects that provided they
had not had fever for 1 week, were not receiving any medica-
tions, were not be pregnant and did not have a history of any
chronic diseases.
All patient samples, as well as samples from the healthy
volunteers, were collected under the Ethics Committee of the
Medical University of Bialystok upon signing an approved
protocol and a written informed consent form in accordance
with the Declaration of Helsinki, No. R-I-002/218/2007.
Methods
The cytokine was collected at the time of diagnosis (76
patients) and after induction (71 patients), approximately 28
±2 days after the beginning of treatment. The measurement
was done following the manufacturers’ instructions. Four
independent sets of experiments were performed. Each exper-
iment included the kit’s standards run in triplicate and samples
both from the AML patients and healthy controls. No signif-
icant variations were observed among the experiments.
Quantitative assessments of cytokines were performed by
means of ELISA assays. Soluble APRIL concentrations were
measured in the serumwith Human APRIL (Platinum ELISA,
eBioscience Austria). Soluble TRAIL, BAFF, IL-6 and TNF
were evaluated in the serum using commercially available test
kits (Quantikine®, R&D kits, Minneapolis, MN, USA).
Statistics
Results were expressed as median (range). The chi-square or,
alternatively, the Kruskal–Wallis test was used to assess rela-
tionships between categorical variables. Comparisons be-
tween the AML and the control groups were made using the
non-parametric Mann–Whitney test. The Spearman’s order
correlation coefficient was applied to determine correlations
between the measured parameters. Survival times were com-
pared by means of the log-rank test. Multivariate models were
reduced by one factor at a time to ensure that all the factors
remaining in the model were statistically significant at the 5 %
level. p Values below 0.05 were considered to be statistically
significant. Descriptive statistics were analysed, and univari-
ate analyses were performed.
Results
SerumAPRIL, BAFF, TRAIL, TNF-α and IL-6 concentration
Median (range) serum values of BAFF, APRIL, TRAIL, IL-6,
TNF-α of AML patients and healthy volunteers are listed in
Table 2. Pre-treatment AML patients had a significantly higher
serum concentration compared to healthy volunteers for BAFF,
3,651.1 pg/ml (983.9–9151.4 pg/ml) versus 651.4 pg/ml (362.9–
1,122.3 pg/ml), p<0.0001; APRIL, 5.96 ng/ml (1.65–
43.4 ng/ml) versus 1.68 ng/ml (1.0–7.56 ng/ml), p<0.0001;
Table 1 Characteristics of patients with AML
Characteristic AML
Number of patients 76
Mean (range) age, year 45.5 (18–62)
Mean (±SD) white blood cell count (G/l) 32.01±28.04
Mean (range) of the blastic cells in
peripheral blood (range)
49 (0–93)
Mean (range) of blastic cells in bone
marrow (range)
55 (20–98)
Acute myeloid leukaemia with
recurrent genetic abnormalities
n (%)
t(8;21) (q22;q22);(AML1/ETO) 10 (13.1 %)
inv(16) (p13;q22) or t(16;16)
(p13;q22); (CBFß/ MYH11)
2 (2.6 %)
t(9;11); MLLT3-MLL 3 (4.0 %)
AML with multilineage dysplasia
without antecedent MDS
1 (1.3 %)
AML therapy-related 0 (0.0 %)
AML not otherwise categorized 61
AML, minimally differentiated 8 (10.5 %)
AML without maturation 13 (17.1 %)
AML with maturation 20 (26.3 %)
Acute myelomonocytic leukaemia (AMMoL) 14 (18.4 %)
AMMoL with eosinophilia 0 (0.0 %)
Acute monoblastic leukaemia 2 (2.6 %)
Acute monocytic leukaemia 2 (2.6 %)
Acute erythroid leukaemia 1 (1.3 %)
Acute megakaryoblastic leukaemia 0 (0.0 %)
Outcome of induction therapy, n
CR achieved after first induction 44
CR achieved after second induction 12








Favorable risk 13 (17.0 %)
Intermediate risk I 17 (22.5 %)
Intermediate risk II 13 (17.0 %)
Unfavourable risk 33 (43.5 %)
AML acute myeloid leukaemia, CR complete remission, AlloHSCT allo-
genic haematopoietic stem cell transplantation, NPM1mut mutated
nucleophosmin, CEBPAmut mutated core-binding factor leukaemia,
FLT3-ITD internal tandem duplication of Fms-like tyrosine kinase 3
Ann Hematol (2015) 94:35–43 37
IL-6, 12.12 pg/ml (1.96–43.4 pg/ml) versus 1.92 pg/ml (0.87–
2.43 pg/ml), p<0.001; and TNF-α, 9.06 pg/ml (3.92–83.4 pg/
ml) versus 5.35 pg/ml (3.12–7.4 pg/ml), p=0.04. On the other
hand, the study did not show meaningful differences between
AML patients compared to healthy volunteers for TRAIL:
68.54 pg/ml (19.1–104.8 pgml) versus 79.9 pg/ml (55.4–
108.2 pg/ml), p=0.12 (Table 2). Moreover, none of the analyses
exhibited any marked differences in the concentration of cyto-
kines according to the WHO classification for all studied cyto-
kines (p>0.05).
In addition, the concentration of BAFF and IL-6 in the
group of newly diagnosed patients differed sharply from that
of patients after chemotherapy, for BAFF, p=0.02, and IL-6,
p=0.0001, respectively. Pronounced differences were ob-
served also between the subgroup of patients with CR and
NR. The concentrations were found to be lower in the former,
for BAFF, 1,885.1 pg/ml (972.3–7,645.4 pg/ml) versus
5,036.4 pg/ml (1,538.2–8,923.4 pg/ml); IL-6, 5.42 pg/ml
(0.57–20.1 pg/ml) versus 19.4 pg/ml (4.57–155.4 pg/ml),
p=0.001; and for APRIL, 3.42 ng/ml (1.4–19.2 ng/ml) versus
8.89 ng/ml (2.1–69.9 ng/ml), p=0.04, but not for TNF-α, p=
0.23. Conversely, the concentration of TRAIL in the CR
subgroup was meaningfully higher compared to the NR one:
74.4 pg/ml (35.22–158.8 pg/ml) versus 50.56 pg/ml (19.3–
88.28 pg/ml), p=0.02 (Table 2).
Correlation with clinical and laboratory data
We subsequently evaluated the association of each cytokine
under scrutiny with a series of clinical and haematological
variables of well-known parameters of prognosis and tumour
load in AML (presented in Table 1). The study did not estab-
lish significant differences within the subgroup of patients
with different types of cytogenetic risk (favourable vs
intermediate I and II vs unfavourable), p>0.05 except for
the concentration of TRAIL. The median concentration of
TRAIL in the favourable cytogenetic risk group, the interme-
diate I plus II and unfavourable group was established, stand-
ing at 77.1 pg/ml (43.3–104.8 pg/ml), 52.1 pg/ml (22.3–
92.3 pg/ml) 5 and 45.6 pg/ml (19.1–88.3), p=0.03, respec-
tively. More importantly, the study did not establish signifi-
cant differences in concentrations connected with the presence
of internal tandem duplications of FLT3 mutations, p>0.05.
Statistic analyses were not done for NMP1 and CEBPA due to
a small number of patients with positive mutations.
Furthermore, the study demonstrated statistically signifi-
cant correlations between the concentration of TNF-α, BAFF
and TRAIL versus the WBC counts (rho=0.33, p=0.04 and
rho=0.58, p<0.001 and rho=−0.56, p<0.001, respectively).
It also revealed a significantly positive correlation between the
concentration of TNF-α and BAFF versus neutrophil counts
(rho=0.33, p=0.04, rho=0.47, p<0.001) and a negative one
with TRAIL (rho=−0.35, p=0.01).
In addition, the analyses showed a meaningful positive
correlation between monoblastic cell counts and the concen-
tration of BAFF (rho=0.37, p=0.01) and a negative one with
TRAIL (rho=−0.42, p=0.007). Even more importantly, the
study revealed a positive correlation between the concentra-
tion of APRIL and the counts of blastic cells in a bone marrow
smear (rho=0.43, p=0.001 and a negative one between the
concentration of TRAIL and blastic cell counts in peripheral
blood (rho=−0.41, p=0.002) and LDH (rho=−0.52,
p<0.001).
What is more, the concentration of BAFF was found to
correlate significantly and positively with the concentration of
APRIL (rho=0.53, p<0.001) and TNF (rho=0.42, p=0.002)
and negatively with TRAIL (rho=−0.43, p=0.001). We also
established a meaningful negative correlation between TRAIL
Table 2 The median (range) values of chosen parameters of AML patients and healthy volunteers





Patients after an induction treatment
After the treatment n=71 With CR n=44 With NR n=27
TRAIL [pg/ml] 68.54 (19.1–104.8) 79.9* (55.4–108.2) 56.52 (19.3–158.8) 74.2 (35.22–158.8) 50.56*** (19.3–88.28)
BAFF [pg/ml] 3615.1 (983.9–9151.4) 651.4* (362.9–1122.3) 3058.1** (972.3–8923.4) 1885.1 (972.3–7645.4) 5036.4*** (1538.2–8923.4)
APRIL [ng/ml] 5.96 (1.65–43.4) 1.68* (1.0–7.56) 5.56 (1.4–69.9) 3.42 (1.4–19.2) 8.89*** (2.1–69.9)
TNF [pg/ml] 9.06 (3.92–83.4) 5.35 * (3.12–7.4) 8.62** (3.8–69.1) 8.51 (3.8–43.1) 9.13 (3.9–69.1)
IL-6 [pg/ml] 12.12 (1.96–43.4) 1.92* (0.87–2.43)* 8.64** (0.57–155.4) 5.42 (0.57–20.1) 19.4*** (4.57–155.4)
The values are presented as median (range)
AML acute myeloid leukaemia, BAFF B cell-activating factor, APRIL a proliferation-inducing ligand, TRAIL TNF-related apoptosis-inducing ligand,
TNF tumour necrosis factor, IL-6 interleukin 6, CR complete remission, NR non-responders
*p<0.05 between AML patients and healthy volunteers
**p<0.05 between before and after treatment AML patients
***p<0.05 between patients with CR and NR
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and IL-6 versus TNF-α (for both rho=−0.31, p=0.04) and a
positive one between IL-6 and BAFF (p=0.02). There was,
however, no correlation between IL-6 and APRIL (p>0.05).
Prognostic impact of cytokines on overall survival
In the AML group, the favourable cytogenetic risk subgroup
is usually excluded from the analysis due to its different
biology and outcome. However, there was no change in the
value of all the cytokines, except for TRAIL, in predicting
survival after these patients had been excluded. Additionally,
we observed that pre-treatment AML patients with serum
BAFF values higher than the median (3,615.14 pg/ml) had a
significantly shorter overall survival (OS) than patients with a
lower BAFF value, p=0.03 (Fig. 1). Furthermore, we found
that pre-treatment AML patients with serum TRAIL values
lower than the median (68.54 pg/ml) had a significantly
shorter OS than patients with a higher TRAIL value, p=0.03
(Fig. 1). In the subgroups of APRIL patients, there were no
statistically significant differences in the median values
(5.96 ng/ml) of APRIL, p=0.61 with regard to OS. As ex-
pected, cytogenetic turned out to be a strong predictor of
survival in this group of patients (p<0.001). By contrast,
LDH, age and WBC were not found to be predictors of
survival. Multivariate Cox proportional hazard model, which
incorporates all significant factors along with the studied
cytokines, showed that only TNF-α and BAFF can be con-
sidered independent risk factors of cytogenetic, performance
status or age (Table 3).
Discussion
Over the last few decades, countless attempts have been made
at establishing prognostic markers capable of discriminating
high-risk patients and at identifying a new complex network
of cytokines that either promote or inhibit AML cell growth,
progression and the development of drug resistance or sensi-
tivity. Among these cytokines, TRAIL, a member of the TNF
family, has emerged as a prominent biologically targeted anti-
tumour protein by virtue of its remarkable ability to induce
apoptosis in a variety of human cancer cell lines without
affecting normal cells [8]. In recent years, TRAIL has raised
hopes for its therapeutic potential as an anti-neoplastic agent
in different types of tumours, including haematological ma-
lignancies, such as AML [30]. The in vitro cytotoxic response
of AML cell lines to recombinant TRAIL varies from good to
moderate [31, 32]. However, a number of in vitro studies have
convincingly shown AML primary cells to be resistant to the
proapoptotic activity of TRAIL used as a single agent, despite
the presence and functioning of the TRAIL death pathway.
Lack of sensitivity to the TRAIL apoptotic pathway can be
explained by different mechanisms involving reduced expres-
sion of the death receptors (only a minority of the AML cells
express TRAIL-R1 and TRAIL-R2) [33]. On the other hand, it
has been recently demonstrated that TRAIL sensitivity of
AML blasts could be increased by co-treatment with a cyto-
toxic drug even those who are refractory to conventional
chemotherapy [33, 34]. Indeed, Chamuleau et al. confirmed
the anti-apoptotic function of decoy TRAIL-R3 in vitro by
treating leukaemic cell lines and fresh primary AML samples
with recombinant soluble TRAIL. They have provided new
evidence indicating that direct targeting of proapoptotic re-
ceptors may be an option in the treatment of AML patients.
Even more importantly, they established that high expression
of the decoy receptor R3 has impact on poor clinical outcome
in AML [35].
To the best of our knowledge, there is no data describing
the concentration of TRAIL in AML patients or its possible
application on biological and clinical features of AML. In this
respect, our study revealed significantly lower concentrations
of soluble TRAIL in 76 AML patients compared to healthy
volunteers. Second, the data showed that the concentration of
Fig. 1 Kaplan–Meier curves of overall survival estimates according to
TRAIL, BAFF and APRIL serum levels, in patients with newly diag-
nosed acute myeloid leukaemia. Patients with TRAIL values higher
(upper or black line) than median (38.54 pg/ml) have a significant longer
OS than patients with lower TRAIL value (bottom line or red line). The
two curves are significantly different (p=0.03). Patients with BAFF
values higher (bottom or black line) than median (3,615.14 pg/ml) have
a significant shorter OS than patients with lower BAFF value (upper line
or red line). The two curves are significantly different (p=0.03). There
were no differences of OS between patients with higher values of APRIL
than median (5.96 ng/ml) compared to lower values, p=0.6
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TRAIL following the administration of induction therapy in
the subgroup of CRwas meaningfully higher compared to NR
and nearly equalled the value in healthy volunteers. Even
more importantly, it became clear that TRAIL concentration
correlated negatively with risk factors, such as high WBC
count and LDH, both of which have prognostic values and
are associated with adverse outcomes in AML. Furthermore,
based on the obtained data, we found a relevant negative
correlation between the concentration of TRAIL and blastic
cell counts, as well as meaningful differences within the range
of cytogenetic risk groups, since the concentration in patients
belonging to the favourable risk group was significantly
higher compared to the rest, nearly equaling the values in
healthy volunteers. It must be noted that blocking anti-
TRAIL antibodies markedly reduced or completely inhibited
hypoxia-induced apoptosis in AML1/ETO and that TRAIL is
a key regulator of hypoxia-induced apoptosis in these cells
[36]. All these established correspondences suggest that de-
creased concentration of TRAIL can be considered as a high-
risk factor in patients with AML. Furthermore, the study
found a negative correlation between monoblastic cell counts
and TRIAL. Indeed, the dichotomous effect of TRAIL on
malignant cells (early induction of apoptosis and monocytic
maturation of the surviving cells) might have important ther-
apeutic implications for the treatment of AML [11].Moreover,
in univariate analysis, the data showed that pre-treatment
AML patients with serum TRAIL values higher than the
median had a significantly shorter OS than patients with a
lower TRAIL. The results are not surprising, since the data
established also a negative correlation between TRAIL and
TNF-α concentration, whose increased serum level is an
adverse prognostic factor for survival in AML patients [5].
Summarising the obtained results, we hypothesized that my-
eloid leukaemic blasts may be principally sensitive to TRAIL-
Table 3 Univariate (unadjusted)
and multivariate (adjusted) analy-
sis of associations between con-
centrations of TNF-α superfamily
and overall survival of AML
patients
Low or high superfamily of TNF
refers to values either lower or
higher than median observed in
all AML patients at the time of
diagnosis
HR hazard rate, AML acute mye-
loid leukaemia, BAFF B cell-
activating factor, APRIL a
proliferation-inducing ligand,
TRAIL TNF-related apoptosis-in-
ducing ligand, TNF tumour ne-
crosis factor, IL-6 interleukin 6
Overall survival
HR 95 % confidence interval p Value
All patients
Univariate analysis
Sex (male vs female) 1.1612 0.51–2.65 0.71
Age (<60 vs 60+) 1.5322 0.66–3.58 0.32
Cytogenetics
Favourable vs adverse 5.7120 1.91–0.15.9 0.0005
Intermediate vs adverse 3.7411 1.59–11.64 0.0040
TNF-α (low vs high) 3.4801 1.36–8.91 0.0009
APRIL (low vs high) 0.8110 0.35–1.84 0.6133
BAFF (low vs high) 2.1711 0.87–4.94 0.0319
TRAIL (low vs high) 0.4667 0.19–1.10 0.0369
Multivariate analysis
TNF-α (low vs high) 2.6917 1.05–5.89 0.0482
BAFF (low vs high) 2.5332 1.09–4.98 0.0502
TRAIL (low vs high) 0.7119 0.29–1.72 0.2912
Patients without favourable prognostic factors: inv(16) and t(8;21)
Univariate analysis
Sex (male vs female) 1.1708 0.50–2.72 0.701
Age (<60 vs 60+) 1.3520 0.55–3.27 0.512
Cytogenetics
Intermediate vs adverse 3.9751 1.73–13.03 0.0030
TNF-α (low vs high) 2.9247 1.17–5.58 0.0218
APRIL (low vs high) 0.8847 0.38–2.05 0.7745
BAFF (low vs high) 2.4225 0.98–5.99 0.0307
TRAIL (low vs high) 0.5780 0.22–1.410 0.0304
Multivariate analysis
TNF-α (low vs high) 2.6702 1.00–6.75 0.0405
BAFF (low vs high) 2.5365 0.99–6.03 0.0501
TRAIL (low vs high) 0.7092 0.27–1.61 0.3332
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mediated killing by mTRAIL and/or sTRAIL expressed and
secreted by naturally effector immune cells as a part of im-
mune surveillance.
BAFF, a glycoprotein belonging to the TNF family, is
originally expressed as a type II membrane-bound protein,
subsequently cleaved at a putative furin consensus site and
released as a soluble protein [37], playing crucial roles in B
cell homeostasis, tolerance and malignancy. It must be noted
that the regulation of the expression and synthesis of BAFF by
IL-10 and IFN-γ at the transcriptional level has also been
demonstrated in human promyelocytic leukaemia cell cultures
[38]. On the other hand, IL-6 and TNF-a may induce IL-10
secretion with the potential to inhibit IL-6, TNF-α production,
which represents an important amplification loop of the in-
flammatory response [5]. Changes in one of these cytokines
due to a malignancy lead to compensatory mechanisms that
may alter the cytokine network.
The anti-apoptotic activity of APRIL has so far been dem-
onstrated in B lymphoma, multiple myeloma and B-CLL
cells, suggesting a general oncogenic role for APRIL in hae-
matological malignancies. Recently, Boci et al. demonstrated
by means of the Western blotting analysis that exogenous
expression of APRIL upregulated Bcl-2 in CD34+ cells,
whereas APRIL neutralisation resulted in Bcl-2 downregula-
tion in primary AML cells, indicating that APRIL protects
AML from chemotherapeutic drugs through upregulation of
Bcl-2 [26]. Conversely, blocking the function of APRIL by
recombinant soluble APRIL receptors increased the chemo-
therapeutic drug-induced cell death in AML cells. These
results indicate that APRIL acts in an autocrine fashion to
protect AML cells from drug-induced death and foresee a
therapeutic potential of APRIL antagonists in the treatment
of AML.
Our study has been the first to have established the con-
centration of BAFF and APRIL in AML patients, since BAFF
and APRIL are not only a transmembrane proteins but it also
exist in soluble forms derived from the intracellular cleavage
of the full-length protein and confirmed their higher values
compared to healthy volunteers. More importantly, we have
revealed a meaningful decrease in the concentration of BAFF
not APRIL following the administration of induction chemo-
therapy. We further extended this observation by demonstrat-
ing concentrations of APRIL and BAFF to be significantly
lower in the subgroup of patients with CR compared to those
who did not respond to therapy. Furthermore, we found a
correlation between both proteins, and most importantly, be-
tween concentration of BAFF and the growth factor IL-6, a
pleiotropic cytokine with multiple biological activities in vitro
and in vivo, including human myeloid cell proliferation [39].
Since serum levels of IL-6 may reflect the activity of AML, it
is possible that the elevated serum BAFF concentrations
found in untreated patients and statistically higher in active
NR, compared to patients with CR, may be related to the
growth of myeloid cells. More importantly, the study showed
that concentration of BAFF not APRIL was positively asso-
ciated with WBC count and TNF-α concentration at diagno-
sis, what suggest likewise that BAFF is closely related to the
severity and prognosis of the disease. In addition, the study
revealed a positive correlation between the concentration of
APRIL and the counts of blastic cells in a bonemarrow smear,
and a negative one with the concentration of TRAIL, which
was shown to be a prognostic factor for OS in AML patients.
Those do not come as a surprise since BAFF and APRIL are a
well-known stimulator factors for B cell homeostasis and
survival through the activation of NF-κB pathway. Indeed,
there is ever more evidence that this pathway activity is also
observable in the CD34+ AML cells [22]. Given that NF-κB
activity is not restricted to specific AML subtypes or genetic
abnormalities, it is possible that the signalling is universally
essential for myeloid leukaemia progression.
Furthermore, our analyses established important differ-
ences with regard to OS in subgroups with the cut-off point
as the median of BAFF but not APRIL concentration, since
the patients with a higher concentration had a significantly
shorter OS. Our results fall in line with a study conducted by
Kim et al., who showed in multivariate analysis that serum
BAFF but not APRIL was an independent prognostic factor
for OS and progression-free survival in NHL patients [40].
Therefore, it is reasonable to presume that APRIL and BAFF
may play overlapping and synergetic roles in the pathogenesis
of AML. In fact, it has been reported that BAFF and APRIL
can associate with each other to form a heterotrimer capable of
stimulating B cell proliferation in patients with autoimmune
diseases [41].Whether this heterotrimer exists and plays a part
in AML needs further investigation.
In conclusion, our results have demonstrated that serum
concentrations of all TNF superfamily could constitute a
useful biomarker of AML disease activity and progression.
Pre-treatment concentrations of BAFF and TRAIL could also
serve as a prognostic factor for OS. The ligands may therefore
be a novel therapeutic target in AML.
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